EVOME
MEDICAL TECHNOLOGIES INC.

Innovative Physical Therapy Devices Designed to Improve Patient Outcomes & Enhance Clinic Revenues

BIODEX®
An Evome Medical Technologies Company

CORPORATE PRESENTATION | AUGUST 2024

TSXV: EVMT

DISCLAIMER

- DISCLAIMER: This presentation (the "Presentation") about Evome Medical Technologies Inc. ("Evome" or the "Company") is dated as of August 15, 2024. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor.
- No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. The Company does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The contents of this Presentation are not to be construed as legal, financial or tax advice. The information contained herein is considered current as of the date of this Presentation but will not be updated at any time thereafter. This Presentation does not contain all of the information that would normally appear in a prospectus or offering memorandum under applicable Canadian securities laws or registration statement under applicable U.S. securities laws. This Presentation contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate. By your acceptance of this presentation you and any person reviewing this Presentation agrees not to distribute, copy; reproduce; transmit; make available; or condone any of the foregoing, without the prior written consent of the Company. Any unauthorized use of this Presentation is strictly prohibited. On your rights, you are encouraged to review this disclosure and are advised to consult independent legal counsel, tax, accounting and other advisors.
- This Presentation is not, and under no circumstances is to be construed as, a prospectus, offering memorandum, or an advertisement or a public offering of securities, and does not constitute an offer for the sale of securities.
- CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION AND FORWARD-LOOKING STATEMENTS: Certain statements contained in this Presentation constitute "forward-looking statements" and "forward-looking information" as such term is defined in applicable Canadian securities legislation, respectively. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company, including; information relating to the business plans of the Company and the timeline of such plans, including, without limitation a plan to sell any subsidiaries and plans to acquire any new businesses; and anticipated trends in the Company's industry; are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including: acquisition targets achieving results at least as good as their historical performances; the financial information regarding targets being verified when included in the Company's consolidated financial statements prepared in accordance with GAAP; successfully executing on current growth plans; and the Company successfully identifying a buyer for a non-core business and negotiating and closing a sale. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: credit; market (including equity, commodity, foreign exchange and interest rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with United States Securities and Exchange Commission and available at www.sec.gov, and/or with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this Presentation is made as of the date of this Presentation and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
- There can be no assurance that any acquisitions or dispositions (including the proposed disposition of DaMar disclosed herein) by the Company will be completed or the sale price or timing of any transaction and no definitive agreements have been executed. Completion of any transaction will be subject to, amongst other things, negotiation and execution of definitive agreements, and applicable director, shareholder and regulatory approvals.
- This Presentation refers to "Adjusted EBITDA" which is a non-GAAP and non-IFRS financial measure that does not have a standardized meaning prescribed by GAAP or IFRS. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies. This non-GAAP financial measure assists the Company's management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition plans that are fundamentally different from the ongoing operating plans of the Company. The Company's management also believes that presenting this measure allows investors to view the Company's performance using the same measures that the Company uses in evaluating its financial and business performance and trends. "Adjusted EBITDA" is defined as net loss excluding interest expense, provision for income taxes, depreciation of property and equipment, amortization of right-of-use asset, amortization of intangible asset, foreign exchange (loss) gain, other income, provision for impairment, change in fair value of contingent consideration, transaction costs, gain/loss on sale of business and stock-based compensation. Please see the Company's press release dated August 12, 2024 for a table that provides reconciliation between net income (loss) and Adjusted EBITDA.
- Unless otherwise specified, all dollar amounts in this Presentation are expressed in United States dollars.

THE RECOVERY SCIENCE MARKET

PREVENTION

TREATMENT

REHABILITATION

US MARKET - $45B WITH 4% CAGR[1]

- 1.6 million registered physical therapists worldwide[1]
- 35 million unique patients per week or about 15% of the US adult population[1]
- Number of physical therapists & athletic trainers entering the market is expected to grow by 20-30% over the next 5 years[1]

CUSTOMERS

- Physical therapy clinics
- Athletic training rooms
- Orthopedic surgeons/sports medicine clinics
- Hospitals/ambulatory surgery centers
- Chiropractic centers

1. Market size: https://www.grandviewresearch.com/industry-analysis/us-physical-therapy-services-market-report

EVOME MEDICAL TECHNOLOGIES INC.

BIODEX®
An Evome Medical Technologies Company

DAMAR PLASTICS
FROM VISION TO REALITY

South Dakota Partners

The Biodex® brand name has been the gold standard[1 2] in physical medicine equipment for over 30 years, with a comprehensive global distribution network.

1. The Ohio State University – Wexner Medical Center Biodex Isokinetic Dynamometry is the "gold standard" (Page 15-16, Appendix E & F) Simple Meniscus Repair: Clinical Practice Guideline | 2. "Isokinetic muscle strength testing…is measured using isokinetic systems such as Biodex or Cybex is the gold standard of muscle testing." Sheeran, Liba, et al. "Chapter 18 OSTEOARTHRITIS AND JOINT REPLACEMENT." Exercise Management for Referred Medical Conditions, Routledge, New York, NY, 2022, 405-405. https://doi.org/10.4324/9781315102399

BUSINESS STABILIZATION, BUILDING ON A PLATFORM

Evome has completed its stabilization which began in July 2023 and ended June 2024

Investment Highlights

Generated positive Adjusted EBITDA[1] 3 of the last 4 quarters[2]; core business (Biodex®) solidified breakeven revenue at **CA$1.5M per month** (or CA$4.5M per Q); **Q2 Revenue was CA$6.1M** for Biodex®

Proactively addressing debt reduction with an intention to sell non-core assets (DaMar, South Dakota Partners)

Retained a **globally recognized brand** name in Biodex®

Serviced over **15,000 total customers** over 30 years with Biodex® product

1. Non-GAAP financial measure. | 2. The Company achieved positive Adjusted EBITDA in Q3 2023, Q4 2023 and Q2 2024, following a retooling effort in Q1 2024. See Evome news release dated August 12, 2024.

2ND QUARTER FINANCIAL SNAPSHOT

Evome Financial Highlights Q2 2024[1]

Generated $10.5M in Revenue

- $6.1M from core business Biodex®
- 59% in revenue growth over the prior quarter

Generated $3.3M Gross Margin

- $2.3M from core business Biodex®
- Biodex® had growth of 104% over prior quarter

Generated $421,000 in Adjusted EBITDA in Q2 2024

- $1.7M growth over the prior quarter for core business Biodex®
- Biodex® had year over year growth of 184% over Q2 2023

Debt Was Reduced In Q2 2024 By $2.7M

- $2.6M was from acquisition debt and $0.2M was from debt related to the Company's credit line
- Additional reduction of $900,000 to the credit line in July 2024
- Management plans to continue to use cash from operations as well as plans to sell DaMar Plastics to reduce total debt

Break even for the core business Biodex® is Revenue CA$1.5M per month (CA$4.5M per quarter)

- Biodex® had Q2 2024 Revenue CA$6.1M (34% over breakeven)

1. See Evome news release dated August 12, 2024, which includes GAAP reconciliation.

PLANNED DAMAR SALE TARGETED TO ELIMINATE REMAINING ACQUISITION DEBT

DaMar Overview

- Custom Plastics Manufacturer: Medical and Consumer Products
- Revenue : Q2 2024 $2.1M; $2.0M Q1 2024
- EBITDA: Q2 2024 $0.5M: $0.4M Q1 2024

DaMar Sale Targets

- Market company sale Q1 2025
- Targeted sale Price $15.1M+
- Current acquisition debt of Evome is US$14.8M

All values $CAD

DaMar Discounted Cash Flow[1]

- Valuation $13.6M
- Key Assumptions:
  - *10y treasury: 4.17%*
  - *Market return: 17.5%*
  - *Growth Rate: 2.5%*
  - *EV/EBITDA: 5x*



1. See DaMar Sale – DCF Valuation slide in appendix. | 2. Figures assume 1.3687 USD to CAD. | 3. Figures assume 1.5002 EUR to CAD.

BIODEX® BUSINESS PROFORMA

Evome with Biodex® only:

In the event of a successful sale of DaMar and reduction of all acquisition debt (in CAD)

Profit & Loss

Annual Revenue | **$27.5M**

Gross Profit | **$10.9M**

Adjusted EBITDA | **$2.1M**

Debt Summary

Asset Based Loan | **$2.7M**

Targeted Balance
Secured by A/R and Inventory Levels

Assumptions: Revenue; assumes $25M ($2.1/month); $2.5M annual licensing and new channels; gross profit 40%, SG&A minimal increase vs 2024

REVENUE GROWTH PLAN

Customer Focused In-licensing
of Novel Products

Leveraging **30 years** of the Biodex® brand

&

An enormous client data base of **15,000+ customers**

WITH LOW CAPEX NEEDED

TURNING BIODEX® INTO A SALES & MARKETING COMPANY

Leveraging the Biodex® brand and 15,000+ client data base



IDENTIFY ADDITIONAL PRODUCTS

- Identify products owned by small, private companies with limited distribution
- Target clinical modalities in orthopedics, neurology, and cardiopulmonary

IN LICENSE/OPTION TO ACQUIRE

- In-license by adding Biodex® brand name
- Targeted gross margin of 25-40%
- Low CapEx requirements
- Option to acquire licensed IP for stock

LEVERAGE SALES AND MARKETING NETWORK

- 52 distributers globally covering 70+ countries
- In-license products quarterly
- 27 targets identified
- 16 initial discussions
- Six NDAs signed

BIODEX®: UNDERSTANDING CUSTOMERS & LEVERAGING STRONG DISTRIBUTION

Established Brand:
- Deep understanding of customer needs
- Experienced global distribution network

Biodex® Patients[1]:
- Primarily aged 65+ (arthritis, osteoporosis, joint replacement)
- Increasing neurological patients (Parkinson's, Alzheimer's, stroke)
- Medicare covers 80%, 57% use private insurance

Biodex® Distribution[2]:
- US: 20 agents/distributors
- Global: 32 distributors in 70 countries
- Established VA distribution and national accounts for large practices

Biodex® Customers[2]:
- 15,000+ unique customers
- 76% of the $34B rehab market is private PT clinics

1. Market size: https://www.grandviewresearch.com/industry-analysis/us-physical-therapy-services-market-report | 2. Internal Biodex® Data

EVOME MANAGEMENT TEAM

Mike Seckler

Chief Executive Officer (CEO)

- Permanent CEO of Evome Medical Technologies (appointed July 2023, after serving as interim CEO for one month)
- Over 30 years in the life sciences industry
- General Manager of $100M Canadian subsidiary of Ferring
- Chief Operating Officer at FerGene, led the global commercialization of ADSTILADRIN
- Leadership roles at Pfizer and Merck in marketing, sales, and market access
- B.S. in Health Sciences and M.B.A. from The Pennsylvania State University

Gordon Bean

Chief Financial Officer (CFO)

- Promoted from VP of Finance to CFO of Evome Medical Technologies in July 2024
- Over 20 years of senior financial leadership across life sciences, manufacturing and professional services
- Corporate Controller $250M revenue PE-Backed company: 3Step Sports
- Corporate Controller for Keolis Transit America a $200M division of Keolis
- Licensed CPA since 2000
- Master’s degree in Accounting from Bentley College (graduated with Distinction)
- Bachelor of Science degrees in Biology and Psychology from Concordia University

EVOME BOARD OF DIRECTORS

Ken Kashkin, MD

Chairman and Executive Director

Baxter | FERRING PHARMACEUTICALS | Abbott

Mike Seckler

Chief Executive Officer and Director

Pfizer | MERCK | FERRING PHARMACEUTICALS

Lana Newishy

Non-Executive Director

AMERICAN EXPRESS | ESTĒE LAUDER

Wayne Anderson

Member of the Board of Directors

MERCK | FERRING PHARMACEUTICALS | Lilly

William Garbarini

Member of the Board of Directors

MERCK | FERRING PHARMACEUTICALS | gsk

CAPITAL STRUCTURE

Common Stock	**59,806,377**
Class A[1]	**22,825,952**
Class A[1] (to be issued)	**4,541,730**
Warrants[1] ($0.69 Weighted Avg. Ex. Price)	**8,291,431**
Stock Options ($0.34 Weighted Avg Ex. Price)	**5,139,954**
Restricted Stock Units	**3,800,000**
Fully Diluted Shares Outstanding	**104,405,444**

Current as of August 14, 2024. | 1. Convertible into common stock.

APPENDIX

DAMAR SALE – DCF VALUATION

ASSUMPTIONS

- 10y treasury at 4.17%. Taken online as of July 29, 2024
- Market Return 17.5%. Split between the private company scaling predictably (15%) and not yet reached scale (20%)
- Growth rate. Used a conservative 2.5%
- EV/EBITA Multiple. Calculated at 5X based on the above Terminal Value assuming perpetual growth

Free Cash Flow

Period	-	1	2	3	4	5
EBIT		200,000	220,000	240,000	260,000	280,000
Tax rate		(50,000)	(55,000)	(60,000)	(65,000)	(70,000)
Depreciation		1,627,302	1,637,302	1,637,302	1,637,302	1,637,302
Amortization		214,602	214,602	214,602	214,602	214,602
Cap Ex		(50,000)	-	-	-	-
Change in non-cash WC		-	-	-	-	-
FCF		**1,941,904**	**2,016,904**	**2,031,904**	**2,046,904**	**2,061,904**

Weighted Avg Cost of Capital

Cost of Equity	21%
E/(D+E)	100%
D/(D+E)	0%
WACC	**21%**

Terminal Value Calculation

EBITDA	2,131,904
Exit Multiple	10,659,520
Perpetuity Growth	11,124,015
Average	**10,891,767**

Discounting Cash Flows

	1	2	3	4	5
Discount Factor	0.82	0.68	0.56	0.46	0.38
PV of FCF	1,598,288	1,366,280	1,132,883	939,305	778,762
PV of TV					4,113,721
Enterprise Value					**9,929,240**